Muciclar (Ambroxol Hydrochloride)

Ambroxol Hydrochloride acts as a mucolytic to improve mucus clearance in various respiratory disorders.

• Acute bronchitis: helps loosen thick mucus, facilitating expectoration and relieving cough.
• Chronic bronchitis: reduces sputum viscosity, aiding airway clearance and improving breathing comfort.
• Chronic obstructive pulmonary disease (COPD): assists in thinning secretions, supporting better ventilation and symptom management.
• Upper respiratory tract infections: eases thick sputum production, promoting more effective cough clearance.

• Ambroxol Hydrochloride stimulates surfactant production by type II pneumocytes and enhances ciliary activity, which together lower mucus viscosity. It also promotes serous fluid secretion in the airways, improving mucociliary transport and facilitating the expectoration of secretions.

Ambroxol Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea
• Metallic or altered taste perception
• Abdominal discomfort
• Diarrhea
• Headache
• Skin rash

Serious or Rare Side Effects

• Allergic reactions, including anaphylaxis
• Severe skin reactions such as Stevens‑Johnson syndrome
• Eosinophilic pneumonia
• Elevated liver enzymes or hepatic dysfunction
• Neutropenia or other blood dyscrasias

When using Ambroxol Hydrochloride, consider the following precautions to ensure safe therapy.

• Assess renal function: adjust use in patients with severe renal impairment.
• Monitor for hypersensitivity: discontinue if rash, itching or swelling occurs.
• Use caution in asthma: may increase bronchial secretions.
• Avoid in known hypersensitivity to ambroxol or excipients.
• Pregnancy and lactation: consult a healthcare professional before use.
• Store at room temperature: keep in original container, protect from moisture and light.

Ambroxol Hydrochloride can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Concurrent use with antitussives containing codeine: may reduce mucolytic effectiveness.
• Combination with other mucolytics (e.g., N‑acetylcysteine): risk of excessive thinning of mucus.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ambroxol plasma concentrations.

Moderate Interactions (Monitor Closely)

• Co‑administration with bronchodilators (e.g., β2‑agonists): monitor for additive respiratory effects.
• Use with NSAIDs: may increase risk of gastrointestinal irritation.
• Concurrent anticoagulant therapy: monitor for any changes in bleeding tendency.